$ANIK (Anika Therapeutics Inc)

$ANIK {{ '2016-03-28T13:22:27+0000' | timeago}} • Announcement

Integrated orthopedic medicines company $ANIK said it received CE Mark approval for CINGAL as a medical device to treat pain associated with osteoarthritis of the knee. CINGAL is the first and only commercially-available combination viscosupplement, formulated with $ANIK's proprietary cross-linked sodium hyaluronate and triamcinolone hexacetonide.

$MOH {{ '2018-01-11T21:46:24+0000' | timeago}} • Announcement

$MOH said COO Terry Bayer will be retiring in the next several weeks. The corporate COO role will no longer be a part of $MOH's organizational structure. This is consistent with the company's shift to a flatter organizational structure that will enable the CEO to be more directly involved with business and health plan operations.

$BSX {{ '2018-01-09T20:36:17+0000' | timeago}} • Announcement

Healthcare solutions firm $BSX said its 4Q17 sales is estimated to have grown about 8% YoY, on a reported basis, to $2.41Bil. In the whole of fiscal 2017, sales advanced 8% annually to $9.05Bil. The growth reflects strong sales performance by all product groups.

$MSA {{ '2018-01-09T19:42:03+0000' | timeago}} • Announcement

$MSA BoD declared 1Q18 dividend of 35 cents per share on common stock. The dividend is payable March 10, 2018 to shareholders of record on February 14, 2018.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$BAX {{ '2018-01-08T14:03:11+0000' | timeago}} • Announcement

$BAX will acquire two products from Mallinckrodt plc, RECOTHROM Thrombin topical and PREVELEAK Surgical Sealant, for an upfront payment of approx. $153MM and potential contingent payments in future. The deal is expected to be modestly accretive to 2018 adjusted earnings and increasingly accretive thereafter and is expected to close in 1H18.

$PRGO {{ '2018-01-08T12:05:55+0000' | timeago}} • Announcement

$PRGO named Uwe Rohrhoff as CEO, effective Jan. 15, 2018, following the retirement of John Hendrickson. Rohrhoff was the former CEO at Gerresheimer AG. Hendrickson to remain with the company until March 15, 2018 to ensure successful transition.

$OMI {{ '2018-01-05T13:04:48+0000' | timeago}} • Announcement

Healthcare solutions firm $OMI plans to organize into two units, named Global Solutions and Global Products. The move is in connection with the acquisition and integration of Halyard Health’s Surgical & Infection Prevention business. Global Solutions will contain most of Owens’ legacy business, while Global Products will contain its S&IP business.

$PFE {{ '2018-01-04T13:11:11+0000' | timeago}} • Announcement

Arvinas LLC collaborates with $PFE for the discovery and development of drug candidates using Arvinas' PROTAC Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Arvinas may receive up to $830MM in upfront and potential development and commercialization milestone payments.

$BDX {{ '2017-12-29T16:54:30+0000' | timeago}} • Announcement

$BDX acquired $BCR. Beginning with 2Q18, $BDX will report a new Interventional segment structure, which will include a majority of Bard offerings, with the remainder being reported under the Medical segment.

$BDX {{ '2017-12-29T16:54:14+0000' | timeago}} • Announcement

$BDX has acquired $BCR. $BDX does not expect the acquisition to have a material impact on its financial results in 1Q18. $BDX expects the transaction to generate low-single digit accretion to adjusted EPS in FY18, and high-single digit accretion in FY19.

$BDX {{ '2017-12-29T16:53:59+0000' | timeago}} • Announcement

$BDX completed the acquisition of $BCR. Under the terms of the transaction, Bard became a wholly owned subsidiary of $BDX, and each outstanding share of Bard common stock was converted to the right to receive $222.93 in cash without interest, and 0.5077 of a share of $BDX common stock. Bard shares will cease trading and be delisted from the NYSE.

$BDX {{ '2017-12-28T12:35:48+0000' | timeago}} • Announcement

$BDX gets clearance from the Ministry of Commerce of the People's Republic of China (MOFCOM) to acquire $BCR. BD and Bard expect the proposed acquisition to close on Dec. 29. Separately, BD's proposed divestiture of its soft tissue core needle biopsy product line to Merit Medical is conditioned on MOFCOM approval of Merit as the purchaser.

$ANIK {{ '2017-12-27T17:14:26+0000' | timeago}} • Announcement

Orthopedic medicines company $ANIK said that its HA-based bone void filler has received 510(k) clearance from the U.S. Food and Drug Administration. Anika's bone repair treatment is an injectable, HA-based, settable osteoconductive calcium phosphate bone graft substitute material indicated for filling bone voids of the skeletal system.

$PFE {{ '2017-12-26T12:25:28+0000' | timeago}} • Announcement

$PFE and $MRK announced that the US FDA has approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets for adults with type 2 diabetes.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$MRK {{ '2017-12-22T16:34:34+0000' | timeago}} • Announcement

$MRK and $PFE announced that the FDA approved STEGLATROTM (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.

$PFE {{ '2017-12-21T21:14:41+0000' | timeago}} • Announcement

$PFE announced that the US FDA has granted Breakthrough Therapy Designation for avelumab in combination with INLYTA for treatment-naive patients with advanced renal cell carcinoma (RCC). This is the second Breakthrough Therapy Designation granted to avelumab.

$PFE {{ '2017-12-20T12:23:04+0000' | timeago}} • Announcement

The US FDA has approved $PFE's supplemental New Drug Application to expand the indication for BOSULIF  to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph CML).

$PFE {{ '2017-12-18T19:31:58+0000' | timeago}} • Announcement

The BoD of $PFE has increased the quarterly dividend by 6% to $0.34 per share. The first quarter 2018 cash dividend will be payable on March 1, 2018, to shareholders of record on Feb. 2, 2018. The board also authorized a new $10Bil share repurchase program, in addition to the $6.4Bil remaining under the current authorization.

$MSA {{ '2017-12-14T15:07:35+0000' | timeago}} • Announcement

$MSA's BoD has elected Nishan J. Vartanian as a director of the company. Mr. Vartanian currently serves as President and COO. His election is part of a planned management succession, and coincides with an announcement made by Chairman and CEO William M. Lambert that he intends to retire as CEO in May of 2018.

Recent Transcripts

CMD (Cantel Medical Corp.)
Thursday, December 7 2017 - 4:00pm
PBYI (Puma Biotechnology, Inc.)
Thursday, November 9 2017 - 9:30pm
PRGO (Perrigo Company Public Limited Company)
Thursday, November 9 2017 - 1:00pm
GMED (Globus Medical, Inc.)
Wednesday, November 8 2017 - 10:30pm
OPK (Opko Health, Inc.)
Wednesday, November 8 2017 - 9:30pm
STAA (STAAR Surgical Company)
Wednesday, November 8 2017 - 9:30pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
IRIX (IRIDEX Corporation)
Thursday, November 2 2017 - 9:00pm
MOH (Molina Healthcare, Inc.)
Thursday, November 2 2017 - 9:00pm
NVO (Novo Nordisk A/S)
Thursday, November 2 2017 - 1:16pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, November 2 2017 - 12:30pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
OMI (Owens & Minor Inc.)
Wednesday, November 1 2017 - 12:00pm
NVO (Novo Nordisk A/S)
Wednesday, November 1 2017 - 11:31am
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
TNDM (Tandem Diabetes Care, Inc.)
Thursday, October 26 2017 - 8:30pm
ANIK (Anika Therapeutics Inc)
Thursday, October 26 2017 - 1:00pm
BSX (Boston Scientific Corporation)
Thursday, October 26 2017 - 12:00pm

AlphaGraphics you may like